

Nucleic Acid Based Therapeutics Market Size, Share and Growth Outlook 2026: By Technology, By Application, By Service, By End-Use Industry, Companies to 2034

<https://marketpublishers.com/r/N7F77F7ED180EN.html>

Date: July 2026

Pages: 190

Price: US\$ 3,482.00 (Single User License)

ID: N7F77F7ED180EN

Abstracts

The global Nucleic Acid Based Therapeutics Market size is forecast to increase from \$12.92 Billion in 2026 to \$35.99 Billion in 2034 at a CAGR of 13.66% between 2026 and 2034.

The Nucleic Acid Based Therapeutics market report provides detailed analysis and outlook of Nucleic Acid Based Therapeutics segments including By Technology (RNA-targeted Therapeutics, Gene Therapies, Epigenetic and microRNA Modulating Therapies, Genome Editing Therapies, Others), By Application (Genetic Disorders, Rare Diseases, Cancer, Infectious Diseases, Autoimmune Disorders, Others), By Service (Process Development and Optimization, Manufacturing Services, Analytical and Quality Control Services), By End-Use Industry (Pharmaceutical Companies, Biotechnology Companies, Government and Academic Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Nucleic Acid Based Therapeutics Industry Overview

RNA and Oligonucleotide Medicines Are Redefining Modern Drug Development

The nucleic acid based therapeutics industry has emerged as one of the most innovative segments of biopharmaceutical development, encompassing RNA interference therapies, antisense oligonucleotides, messenger RNA technologies, gene-

silencing medicines, and other sequence-based therapeutic platforms. These treatments are designed to directly modulate disease-causing genetic pathways, enabling highly targeted intervention at the molecular level. Advances in delivery systems, oligonucleotide chemistry, genomic medicine, and precision therapeutics are expanding the applicability of nucleic acid drugs across rare diseases, cardiometabolic disorders, neurological conditions, genetic diseases, and chronic illnesses. Pharmaceutical companies are increasingly investing in platform-based development strategies that leverage genetic insights and sequence-specific targeting to create therapies capable of addressing previously untreatable diseases.

Commercial Success and Clinical Expansion Strengthen Industry Momentum

Commercial execution and pipeline expansion are becoming major drivers of growth within the nucleic acid therapeutics sector. Ionis Pharmaceuticals highlighted the continued advancement of its RNA-targeted portfolio through the launch strategy for DAWNZERO, the first RNA-targeted therapy for hereditary angioedema. The company also outlined plans to expand its independent commercial presence through additional launches involving olezarsen for severe hypertriglyceridemia and zilganersen for Alexander disease. These programs demonstrate how nucleic acid therapeutics are moving beyond rare disease proof-of-concept applications toward broader commercial adoption across multiple therapeutic categories. Simultaneously, Alnylam reported strong growth in global product revenues, supported largely by continued expansion of its transthyretin-focused franchise, reinforcing the commercial viability of RNA interference therapeutics within mainstream healthcare markets.

Artificial Intelligence and Precision Medicine Are Accelerating Therapeutic Discovery

The industry is increasingly integrating artificial intelligence and large-scale genomic datasets into therapeutic development workflows. Alnylam and Inceptiv Nucleics announced a strategic collaboration valued at up to \$2 billion to accelerate RNA interference drug discovery through the combination of proprietary siRNA datasets, RNAi expertise, and foundation models of life. The partnership is specifically designed to optimize oligonucleotide design and increase the speed of sequence-based medicine development. In parallel, Alnylam expanded its precision medicine capabilities through a multi-year agreement with Helix, providing access to deeply phenotyped genomic cohorts that can support target discovery, patient stratification, and clinical development programs. These initiatives reflect a broader industry trend toward combining artificial intelligence, genomic data, and advanced computational biology to improve therapeutic design, accelerate candidate selection, and expand the reach of nucleic acid based

medicines across a growing number of disease areas.

Nucleic Acid Based Therapeutics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Nucleic Acid Based Therapeutics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Alnylam Pharmaceuticals, Inc. , Ionis Pharmaceuticals, Inc. , Sarepta Therapeutics, Inc. , Novartis Pharma AG , Moderna, Inc. , Biogen Inc. , Arrowhead Pharmaceuticals, Inc. , Silence Therapeutics plc , Wave Life Sciences , Stoke Therapeutics, Inc.. The Nucleic Acid Based Therapeutics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Nucleic Acid Based Therapeutics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.

The report provides detailed market analysis including-

- Growth Nucleic Acid Based Therapeutics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Nucleic Acid Based Therapeutics companies

- Porter's Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

- Detailed SWOT Analysis of global and regional Nucleic Acid Based Therapeutics markets

- Competitive analysis including business description, product analysis, and financial profiles

- Key country specific analysis detailing key factors shaping the short-term and long-term outlook

Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Nucleic Acid Based Therapeutics Market Competitive Benchmarking and Company Analysis

Leading companies in Nucleic Acid Based Therapeutics industry include- Alnylam Pharmaceuticals, Inc. , Ionis Pharmaceuticals, Inc. , Sarepta Therapeutics, Inc. , Novartis Pharma AG , Moderna, Inc. , Biogen Inc. , Arrowhead Pharmaceuticals, Inc. , Silence Therapeutics plc , Wave Life Sciences , Stoke Therapeutics, Inc.. The Nucleic Acid Based Therapeutics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Nucleic Acid Based Therapeutics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach \$8.2 Trillion in 2034 from \$5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Nucleic Acid Based Therapeutics market remains one of the strongest-performing segments in the country.

The US Nucleic Acid Based Therapeutics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Nucleic Acid Based Therapeutics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Nucleic Acid Based Therapeutics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for

implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Nucleic Acid Based Therapeutics markets

Canada's strong Nucleic Acid Based Therapeutics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Nucleic Acid Based Therapeutics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada's largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Nucleic Acid Based Therapeutics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Nucleic Acid Based Therapeutics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Nucleic Acid Based Therapeutics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Nucleic Acid Based Therapeutics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Nucleic Acid Based Therapeutics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Nucleic Acid Based Therapeutics sales through 2034

France Nucleic Acid Based Therapeutics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country's National Health Insurance spending target (ONDAM) estimates 3.7% growth in the

country's healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.

The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France's market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Nucleic Acid Based Therapeutics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Nucleic Acid Based Therapeutics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England's plan to give more than 500,000 staff access to new AI tools.

China Nucleic Acid Based Therapeutics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Nucleic Acid Based Therapeutics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Nucleic Acid Based Therapeutics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.

The National Healthcare Security Administration reported that by end-2024, China's

basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Nucleic Acid Based Therapeutics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Nucleic Acid Based Therapeutics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Nucleic Acid Based Therapeutics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Nucleic Acid Based Therapeutics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Nucleic Acid Based Therapeutics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating

investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Nucleic Acid Based Therapeutics Market Segmentation

By Technology

RNA-targeted Therapeutics

Gene Therapies

Epigenetic and microRNA Modulating Therapies

Genome Editing Therapies

Others

By Application

Genetic Disorders

Rare Diseases

Cancer

Infectious Diseases

Autoimmune Disorders

Others

By Service

Process Development and Optimization

Manufacturing Services

Analytical and Quality Control Services

By End-Use Industry

Pharmaceutical Companies

Biotechnology Companies

Government and Academic Research Institutes

Leading Companies in Nucleic Acid Based Therapeutics Industry (2026)

Alnylam Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Sarepta Therapeutics, Inc.

Novartis Pharma AG

Moderna, Inc.

Biogen Inc.

Arrowhead Pharmaceuticals, Inc.

Silence Therapeutics plc

Wave Life Sciences

Stoke Therapeutics, Inc.

Countries Included

North America- US, Canada, Mexico

Europe- Germany, France, UK, Spain, Italy, Nordics, Others

Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia,

Others

Latin America- Brazil, Argentina, Others

Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa,
Other Africa

Key Benefits of Procuring the Analysis

Get Free print authentication across single, multi, and global licenses

Free Accompanying excel spreadsheet with complete quantitative data

Free 2-day consulting support from the lead analyst of the team that developed the report

Strategic Value of the Electrosurgical Generators Market Analysis

Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly

Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry

Stay ahead of competition through a detailed analysis of recent market developments

Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry

Contents

CHAPTER 1- EXECUTIVE SUMMARY

- 1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
- 1.2. Key Industry Highlights, 2026
- 1.3. Premium Market Insights
 - 1.3.1. Potential Nucleic Acid Based Therapeutics Market Types and Applications
 - 1.3.2. Fastest Growing Countries Over the forecast period
- 1.4. Market Scope and Segmentation
 - 1.4.1. Key Market Segments
 - 1.4.2. Key Countries and Regions
 - 1.4.3. Top Companies in the Nucleic Acid Based Therapeutics Industry
- 1.5. Macroeconomic and Demographic Outlook
 - 1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
 - 1.5.2. Population Forecast by Country, 2010- 2040
 - 1.5.3. Inflation Trends in Leading Countries
- 1.6. Impact of Trade Policies, Regulations, and Sustainability
 - 1.6.1. Trade tariffs and localization requirements
 - 1.6.2. ESG and sustainability pressures
 - 1.6.3. Compliance-driven structural changes in the value chain

CHAPTER 2- RESEARCH METHODOLOGY

- 2.1. Report Coverage
- 2.2. Secondary Research
- 2.3. Primary Research
- 2.4. Data Triangulation
- 2.5. Market Modeling and Forecasting

CHAPTER 3- GLOBAL NUCLEIC ACID BASED THERAPEUTICS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034

- 3.1. An Introduction to Global Nucleic Acid Based Therapeutics Markets in 2026
- 3.2. Global Historic and Forecast Nucleic Acid Based Therapeutics Market Size Outlook, USD Million, 2021- 2034
- 3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
- 3.4. Market Dynamics

3.4.1. Key Nucleic Acid Based Therapeutics Market Driving Forces and Their Impact on Market Outlook

3.4.2. Short and Long-Term Trends and Insights Shaping the Future

3.4.3. Potential Nucleic Acid Based Therapeutics Market Opportunities for Industry Stakeholders

3.4.4. Potential Challenges across Nucleic Acid Based Therapeutics Value Chain

CHAPTER 4- NUCLEIC ACID BASED THERAPEUTICS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT

4.1. Porter's Five Forces Analysis

4.1.1. Bargaining Power of Buyers

4.1.2. Bargaining Power of Suppliers

4.1.3. Threat of Substitutes

4.1.4. Threat of New Entrants

4.1.5. Intensity of Competitive Rivalry

4.1.6. Market Attractiveness Analysis by Segment

4.1.7. Market Attractiveness Analysis by Region

4.2. Competitive Landscape

4.2.1 Market Share Analysis of Leading Nucleic Acid Based Therapeutics Companies

4.2.2 Recent Strategic Developments

4.2.3 Mergers, Acquisitions, and Partnerships

4.2.4 Product Launches and Innovation Trends

4.2.5 Key Success Factors

4.3. Value Chain Analysis

4.3.1. Key Value Chain Segments

4.3.2. Dominant players by value-chain stage

4.4. SWOT Analysis

4.4.1. Key Strengths and Opportunities

4.4.2. Major Weaknesses and Threats

4.5 Technology Roadmap

4.6 Regulatory and Reimbursement Landscape

CHAPTER 5- NUCLEIC ACID BASED THERAPEUTICS MARKET OUTLOOK BY SEGMENTS

5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034

5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034

5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034

By Technology
RNA-targeted Therapeutics
Gene Therapies
Epigenetic and microRNA Modulating Therapies
Genome Editing Therapies
Others
By Application
Genetic Disorders
Rare Diseases
Cancer
Infectious Diseases
Autoimmune Disorders
Others
By Service
Process Development and Optimization
Manufacturing Services
Analytical and Quality Control Services
By End-Use Industry
Pharmaceutical Companies
Biotechnology Companies
Government and Academic Research Institutes

CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK

6.1. Base Case Scenario
 6.1.1. Definitions and Insights
 6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
 6.2.1. Definitions and Insights
 6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
 6.3.1. Definitions and Insights
 6.3.2. Market Size Outlook to 2034

CHAPTER 7- NORTH AMERICA NUCLEIC ACID BASED THERAPEUTICS MARKET SIZE ANALYSIS AND OUTLOOK

7.1. North America Nucleic Acid Based Therapeutics Market Overview, 2026
7.2. Leading Companies Operating in North America

7.3. Key Industry Statistics, 2026

7.4. North America Nucleic Acid Based Therapeutics Market Trends and Growth Opportunities to 2034

7.5. North America Nucleic Acid Based Therapeutics Market Size Outlook by Type

7.6. North America Nucleic Acid Based Therapeutics Market Size Outlook by Application

7.7. North America Nucleic Acid Based Therapeutics Market Size Outlook by Country

7.8. United States

7.8.1. Key Statistics

7.8.2. The US Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

7.8.3. Key Market Drivers and Industry Developments in the US Nucleic Acid Based Therapeutics Companies

7.9. Canada

7.9.1. Key Statistics

7.9.2. Canada Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

7.9.3. Key Market Drivers and Industry Developments in Canada Nucleic Acid Based Therapeutics Companies

7.10. Mexico

7.10.1. Key Statistics

7.10.2. Mexico Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

7.10.3. Key Market Drivers and Industry Developments in Mexico Nucleic Acid Based Therapeutics Companies

CHAPTER 8- EUROPE NUCLEIC ACID BASED THERAPEUTICS MARKET SIZE ANALYSIS AND OUTLOOK

8.1. Europe Nucleic Acid Based Therapeutics Market Overview, 2026

8.2. Leading Companies Operating in Europe

8.3. Key Industry Statistics, 2026

8.4. Europe Nucleic Acid Based Therapeutics Market Trends and Growth Opportunities to 2034

8.5. Europe Nucleic Acid Based Therapeutics Market Size Outlook by Type

8.6. Europe Nucleic Acid Based Therapeutics Market Size Outlook by Application

8.7. Europe Nucleic Acid Based Therapeutics Market Size Outlook by Country

8.8. Germany

8.8.1. Key Statistics

8.8.2. Germany Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

8.8.3. Key Market Drivers and Industry Developments in Germany Nucleic Acid Based Therapeutics Companies

8.9. France

8.9.1. Key Statistics

8.9.2. France Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

8.9.3. Key Market Drivers and Industry Developments in France Nucleic Acid Based Therapeutics Companies

8.10. United Kingdom

8.10.1. Key Statistics

8.10.2. United Kingdom Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

8.10.3. Key Market Drivers and Industry Developments in the UK Nucleic Acid Based Therapeutics Companies

8.11. Spain

8.11.1. Key Statistics

8.11.2. Spain Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

8.11.3. Key Market Drivers and Industry Developments in Spain Nucleic Acid Based Therapeutics Companies

8.12. Italy

8.12.1. Key Statistics

8.12.2. Italy Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

8.12.3. Key Market Drivers and Industry Developments in Italy Nucleic Acid Based Therapeutics Companies

8.13. Rest of Europe

8.13.1. Key Statistics

8.13.2. Rest of Europe Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Nucleic Acid Based Therapeutics Companies

CHAPTER 9- ASIA PACIFIC NUCLEIC ACID BASED THERAPEUTICS MARKET SIZE ANALYSIS AND OUTLOOK

9.1. Asia Pacific Nucleic Acid Based Therapeutics Market Overview, 2026

9.2. Leading Companies Operating in Asia Pacific

9.3. Key Industry Statistics, 2026

9.4. Asia Pacific Nucleic Acid Based Therapeutics Market Trends and Growth Opportunities to 2034

9.5. Asia Pacific Nucleic Acid Based Therapeutics Market Size Outlook by Type

9.6. Asia Pacific Nucleic Acid Based Therapeutics Market Size Outlook by Application

9.7. Asia Pacific Nucleic Acid Based Therapeutics Market Size Outlook by Country

9.8. China

9.8.1. Key Statistics

9.8.2. China Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

9.8.3. Key Market Drivers and Industry Developments in China Nucleic Acid Based Therapeutics Companies

9.9. Japan

9.9.1. Key Statistics

9.9.2. Japan Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

9.9.3. Key Market Drivers and Industry Developments in Japan Nucleic Acid Based Therapeutics Companies

9.10. India

9.10.1. Key Statistics

9.10.2. India Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

9.10.3. Key Market Drivers and Industry Developments in India Nucleic Acid Based Therapeutics Companies

9.11. South Korea

9.11.1. Key Statistics

9.11.2. South Korea Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

9.11.3. Key Market Drivers and Industry Developments in South Korea Nucleic Acid Based Therapeutics Companies

9.12. Australia

9.12.1. Key Statistics

9.12.2. Australia Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

9.12.3. Key Market Drivers and Industry Developments in Australia Nucleic Acid Based Therapeutics Companies

9.13. Southeast Asia

9.13.1. Key Statistics

9.13.2. Southeast Asia Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Nucleic Acid Based Therapeutics Companies

CHAPTER 10- SOUTH AND CENTRAL AMERICA NUCLEIC ACID BASED THERAPEUTICS MARKET SIZE ANALYSIS AND OUTLOOK

10.1. South and Central America Nucleic Acid Based Therapeutics Market Overview, 2026

10.2. Leading Companies Operating in South and Central America

10.3. Key Industry Statistics, 2026

10.4. South and Central America Nucleic Acid Based Therapeutics Market Trends and Growth Opportunities to 2034

10.5. South and Central America Nucleic Acid Based Therapeutics Market Size Outlook by Type

10.6. South and Central America Nucleic Acid Based Therapeutics Market Size Outlook by Application

10.7. South and Central America Nucleic Acid Based Therapeutics Market Size Outlook by Country

10.8. Brazil

10.8.1. Key Statistics

10.8.2. Brazil Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

10.8.3. Key Market Drivers and Industry Developments in Brazil Nucleic Acid Based Therapeutics Companies

10.9. Argentina

10.9.1. Key Statistics

10.9.2. Argentina Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

10.9.3. Key Market Drivers and Industry Developments in Argentina Nucleic Acid Based Therapeutics Companies

10.10. Rest of Latin America

10.10.1. Key Statistics

10.10.2. Rest of Latin America Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Nucleic Acid Based Therapeutics Companies

CHAPTER 11- MIDDLE EAST AND AFRICA NUCLEIC ACID BASED THERAPEUTICS MARKET SIZE ANALYSIS AND OUTLOOK

11.1. Middle East and Africa Nucleic Acid Based Therapeutics Market Overview, 2026

11.2. Leading Companies Operating in Middle East and Africa

11.3. Key Industry Statistics, 2026

11.4. Middle East and Africa Nucleic Acid Based Therapeutics Market Trends and Growth Opportunities to 2034

11.5. Middle East and Africa Nucleic Acid Based Therapeutics Market Size Outlook by Type

11.6. Middle East and Africa Nucleic Acid Based Therapeutics Market Size Outlook by Application

11.7. Middle East and Africa Nucleic Acid Based Therapeutics Market Size Outlook by

Country

11.8. Saudi Arabia

11.8.1. Key Statistics

11.8.2. Saudi Arabia Nucleic Acid Based Therapeutics Market Size Outlook, 2021-2034

11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Nucleic Acid Based Therapeutics Companies

11.9. United Arab Emirates

11.9.1. Key Statistics

11.9.2. The UAE Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

11.9.3. Key Market Drivers and Industry Developments in the UAE Nucleic Acid Based Therapeutics Companies

11.10. Africa

11.10.1. Key Statistics

11.10.2. Africa Nucleic Acid Based Therapeutics Market Size Outlook, 2021- 2034

11.10.3. Key Market Drivers and Industry Developments in Africa Nucleic Acid Based Therapeutics Companies

CHAPTER 12- COMPANY PROFILES

12.1. Top Companies in Nucleic Acid Based Therapeutics Industry

Alnylam Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Sarepta Therapeutics, Inc.

Novartis Pharma AG

Moderna, Inc.

Biogen Inc.

Arrowhead Pharmaceuticals, Inc.

Silence Therapeutics plc

Wave Life Sciences

Stoke Therapeutics, Inc.

12.2. Business Description

12.3. SWOT Profiles

12.4. Products and Services

CHAPTER 13- APPENDIX

Glossary of Terms

Research Methodology & Data Sources

Conclusion & Strategic Recommendations

I would like to order

Product name: Nucleic Acid Based Therapeutics Market Size, Share and Growth Outlook 2026: By Technology, By Application, By Service, By End-Use Industry, Companies to 2034

Product link: <https://marketpublishers.com/r/N7F77F7ED180EN.html>

Price: US\$ 3,482.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N7F77F7ED180EN.html>